HOOKIPA PharmaHOOK 49 EBITDA Margin % is -19.46% as of Jun. 2025. GuruFocus rates HOOK with a GF Score™ of 49/100 and a GF Value™ of $2.78 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 945 Biotechnology companies, HOOKIPA Pharma ranks worse than 68.47% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. HOOKIPA Pharma's EBITDA for the
three
months ended in Jun. 2025 was $-1.32 Mil. HOOKIPA Pharma's Revenue for the
three
months ended in Jun. 2025 was $6.80 Mil. Therefore, HOOKIPA Pharma's EBITDA margin for the quarter that ended in Jun. 2025 was -19.46%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
HOOKIPA Pharma EBITDA Margin % Related Terms
HOOKIPA Pharma EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for HOOKIPA Pharma's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HOOK vs LNAI, ZEOX, GDTC: EBITDA Margin % Comparison
For the Biotechnology subindustry, HOOKIPA Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HOOKIPA Pharma EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HOOKIPA Pharma's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where HOOKIPA Pharma's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HOOKIPA Pharma (HOOK) has a EBITDA Margin % of -19.46% as of Jun. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on HOOKIPA Pharma and its competitors. According to the industry distribution chart, HOOKIPA Pharma ranks #647 out of 945 companies in the Biotechnology industry, placing it in the top 68.5%.
Is HOOKIPA Pharma's EBITDA Margin % too high?
HOOKIPA Pharma's current EBITDA Margin % is -19.46%. Based on the distribution chart, HOOKIPA Pharma ranks #647 out of 945 companies in the Biotechnology industry, which is below the industry midpoint. Overall, HOOKIPA Pharma has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HOOKIPA Pharma's EBITDA Margin % compare to LNAI and ZEOX?
According to the Biotechnology industry distribution chart, HOOKIPA Pharma ranks #647 out of 945 companies for EBITDA Margin %. This places HOOKIPA Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on HOOKIPA Pharma and its competitors. HOOKIPA Pharma's current EBITDA Margin % is -19.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HOOKIPA Pharma stock overvalued right now?
Based on GuruFocus' analysis, HOOKIPA Pharma (HOOK) is currently considered Possible Value Trap. The stock's GF Value™ is $2.78, compared to a current price of $1.15 — trading 58.6% below its estimated fair value. The current EBITDA Margin % is -19.46%. HOOKIPA Pharma's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For HOOKIPA Pharma (HOOK), the current EBITDA Margin % is -19.46% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HOOKIPA Pharma (HOOK) Overvalued in 2026?
Based on GuruFocus' analysis, HOOKIPA Pharma stock appears to be undervalued.
The current stock price of $1.15 is trading 58.6% below its estimated GF Value™ of $2.78.
GuruFocus considers HOOKIPA Pharma to be Possible Value Trap.
Key valuation signals for HOOK:
EBITDA Margin %: -19.46%
GF Value™: $2.78 vs. price of $1.15 (58.6% below fair value)
No single metric tells the full story. See the HOOK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company's product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. In addition, It is also focused to develop therapies that are intended to provide functional cures for hepatitis B virus (HBV) and human immunodeficiency virus-1 (HIV-1).
49GF Score
Get the complete analysis for HOOK
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HOOK has been successfully added to your 
